| Tbio | Uveal autoantigen with coiled-coil domains and ankyrin repeats |
Modulates isoactin dynamics to regulate the morphological alterations required for cell growth and motility. Interaction with ARF6 may modulate cell shape and motility after injury. May be involved in multiple neurite formation (By similarity).
This gene encodes a protein that contains ankyrin repeats and coiled coil domains and likely plays a role in apoptosis. Studies in rodents have implicated the encoded protein in the stimulation of apoptosis and the regulation of mammary gland involution, in which the mammary gland returns to its pre-pregnant state. This protein has also been proposed to negatively regulate apoptosis based on experiments in human cell lines in which the protein was shown to interact with PRKC apoptosis WT1 regulator protein, also known as PAR-4, and inhibit translocation of the PAR-4 receptor. Autoantibodies to this protein have been identified in human patients with panuveitis and Graves' disease. Differential expression of this gene has been observed in various human cancers. [provided by RefSeq, May 2017]
This gene encodes a protein that contains ankyrin repeats and coiled coil domains and likely plays a role in apoptosis. Studies in rodents have implicated the encoded protein in the stimulation of apoptosis and the regulation of mammary gland involution, in which the mammary gland returns to its pre-pregnant state. This protein has also been proposed to negatively regulate apoptosis based on experiments in human cell lines in which the protein was shown to interact with PRKC apoptosis WT1 regulator protein, also known as PAR-4, and inhibit translocation of the PAR-4 receptor. Autoantibodies to this protein have been identified in human patients with panuveitis and Graves' disease. Differential expression of this gene has been observed in various human cancers. [provided by RefSeq, May 2017]
Comments
| Disease | Target Count | P-value |
|---|---|---|
| non-small cell lung carcinoma | 317 | 1.1e-24 |
| lung adenocarcinoma | 2716 | 1.6e-11 |
| ovarian cancer | 8520 | 1.5e-06 |
| osteosarcoma | 7950 | 3.0e-06 |
| ependymoma | 4679 | 1.2e-05 |
| tuberculosis | 2010 | 6.0e-05 |
| cystic fibrosis | 1696 | 9.4e-05 |
| glioblastoma | 5792 | 2.9e-04 |
| pancreatic ductal adenocarcinoma liver metastasis | 1962 | 7.3e-04 |
| atypical teratoid / rhabdoid tumor | 5112 | 9.0e-04 |
| primitive neuroectodermal tumor | 3035 | 1.6e-03 |
| pediatric high grade glioma | 1064 | 2.2e-03 |
| pancreatic cancer | 2398 | 3.2e-03 |
| progressive supranuclear palsy | 676 | 7.7e-03 |
| medulloblastoma | 720 | 1.0e-02 |
| invasive ductal carcinoma | 2951 | 2.7e-02 |
| Breast cancer | 3578 | 2.9e-02 |
| Disease | Target Count | Z-score | Confidence |
|---|---|---|---|
| Vogt-Koyanagi-Harada disease | 9 | 3.847 | 1.9 |
| Subacute thyroiditis | 3 | 3.07 | 1.5 |
| Disease | log2 FC | p |
|---|---|---|
| atypical teratoid / rhabdoid tumor | 2.400 | 9.0e-04 |
| Breast cancer | 2.200 | 2.9e-02 |
| cystic fibrosis | -1.156 | 9.4e-05 |
| ependymoma | 1.300 | 1.2e-05 |
| glioblastoma | 1.200 | 2.9e-04 |
| invasive ductal carcinoma | -1.100 | 2.7e-02 |
| lung adenocarcinoma | -1.100 | 1.6e-11 |
| medulloblastoma | 1.300 | 1.0e-02 |
| non-small cell lung carcinoma | -1.200 | 1.1e-24 |
| osteosarcoma | 1.811 | 3.0e-06 |
| ovarian cancer | 2.100 | 1.5e-06 |
| pancreatic cancer | 1.400 | 3.2e-03 |
| pancreatic ductal adenocarcinoma liver m... | 1.193 | 7.3e-04 |
| pediatric high grade glioma | 1.100 | 2.2e-03 |
| primitive neuroectodermal tumor | 1.300 | 1.6e-03 |
| progressive supranuclear palsy | -1.600 | 7.7e-03 |
| tuberculosis | 1.200 | 6.0e-05 |
MKSLKSRLRRQDVPGPASSGAAAASAHAADWNKYDDRLMKAAERGDVEKVTSILAKKGVNPGKLDVEGRS 1 - 70 VFHVVTSKGNLECLNAILIHGVDITTSDTAGRNALHLAAKYGHALCLQKLLQYNCPTEHADLQGRTALHD 71 - 140 AAMADCPSSIQLLCDHGASVNAKDVDGRTPLVLATQMSRPTICQLLIDRGADVNSRDKQNRTALMLGCEY 141 - 210 GCRDAVEVLIKNGADISLLDALGHDSSYYARIGDNLDILTLLKTASENTNKGRELWKKGPSLQQRNLTHM 211 - 280 QDEVNVKSHQREHQNIQDLEIENEDLKERLRKIQQEQRILLDKVNGLQLQLNEEVMVADDLESEREKLKS 281 - 350 LLAAKEKQHEESLRTIEALKNRFKYFESDHLGSGSHFSNRKEDMLLKQGQMYMADSQCTSPGIPAHMQSR 351 - 420 SMLRPLELSLPSQTSYSENEILKKELEAMRTFCESAKQDRLKLQNELAHKVAECKALALECERVKEDSDE 421 - 490 QIKQLEDALKDVQKRMYESEGKVKQMQTHFLALKEHLTSEAASGNHRLTEELKDQLKDLKVKYEGASAEV 491 - 560 GKLRNQIKQNEMIVEEFKRDEGKLIEENKRLQKELSMCEMEREKKGRKVTEMEGQAKELSAKLALSIPAE 561 - 630 KFENMKSSLSNEVNEKAKKLVEMEREHEKSLSEIRQLKRELENVKAKLAQHVKPEEHEQVKSRLEQKSGE 631 - 700 LGKKITELTLKNQTLQKEIEKVYLDNKLLKEQAHNLTIEMKNHYVPLKVSEDMKKSHDAIIDDLNRKLLD 701 - 770 VTQKYTEKKLEMEKLLLENDSLSKDVSRLETVFVPPEKHEKEIIALKSNIVELKKQLSELKKKCGEDQEK 771 - 840 IHALTSENTNLKKMMSNQYVPVKTHEEVKMTLNDTLAKTNRELLDVKKKFEDINQEFVKIKDKNEILKRN 841 - 910 LENTQNQIKAEYISLAEHEAKMSSLSQSMRKVQDSNAEILANYRKGQEEIVTLHAEIKAQKKELDTIQEC 911 - 980 IKVKYAPIVSFEECERKFKATEKELKDQLSEQTQKYSVSEEEVKKNKQENDKLKKEIFTLQKDLRDKTVL 981 - 1050 IEKSHEMERALSRKTDELNKQLKDLSQKYTEVKNVKEKLVEENAKQTSEILAVQNLLQKQHVPLEQVEAL 1051 - 1120 KKSLNGTIENLKEELKSMQRCYEKEQQTVTKLHQLLENQKNSSVPLAEHLQIKEAFEKEVGIIKASLREK 1121 - 1190 EEESQNKMEEVSKLQSEVQNTKQALKKLETREVVDLSKYKATKSDLETQISSLNEKLANLNRKYEEVCEE 1191 - 1260 VLHAKKKEISAKDEKELLHFSIEQEIKDQKERCDKSLTTITELQRRIQESAKQIEAKDNKITELLNDVER 1261 - 1330 LKQALNGLSQLTYTSGNPTKRQSQLIDTLQHQVKSLEQQLADADRQHQEVIAIYRTHLLSAAQGHMDEDV 1331 - 1400 QEALLQIIQMRQGLVC 1401 - 1416 //
